Media
Home
Media
- Press
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and MacauSperogenix will receive exclusive rights to develop and commercialize leriglitazone ...23/09/2020
Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trialPediatric Investigational Plan (PIP) for leriglitazone in X-ALD approved by ...12/05/2020
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALDLeriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective ...09/01/2020Read more
- Events
Events in 2021
Events in 202013 Sep 2020 - 17 Sep 2020Movement Disorder SocietyPHILADELPHIA16 Jan 2020 - 17 Jan 2020Aidan Jack Seeger FoundationNEW YORKEvents in 201911 Nov 2019 - 13 Nov 2019BIO-Europe 2019HAMBURG11 Nov 2019 - 13 Nov 2019World Orphan Drug CongressBARCELONA